Introduction {#sec1-1}
============

**What was known?**

Antibiotic resistance in acne patients is a global phenomenonMacrolides and clindamycin are found to be commonly resistant to in various studies across the worldThe use of benzoyl peroxide and retinoids can help obviate resistance.

Antibiotic resistance in acne has been reported from across the globe\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\] and is dependent on multiple factors including variable prescription practices,\[[@ref1][@ref2][@ref3][@ref6][@ref7][@ref16]\] patient compliance,\[[@ref1][@ref2][@ref3][@ref6][@ref7]\] use of concomitant therapy,\[[@ref1][@ref2]\] and also on the methods adopted for isolation of (surface or follicular isolation).\[[@ref22]\]

A crucial determinant of resistance is the method of assessing the minimum inhibitory concentration (MIC) levels, which is not uniform across studies,\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\] with some using CLSI\[[@ref23]\] or EUCAST,\[[@ref24]\] while others using country specific or self-devised MIC values.\[[@ref13][@ref14][@ref15][@ref16][@ref25]\] Conversely, some authors believe that the role of *Propionibacterium acnes* may be overestimated\[[@ref26]\] and it may be useful to administer therapies that do not target *P. acnes*, like retinoids, benzoyl peroxide (BPO), and other nonantibiotics (Zn).\[[@ref27]\]

The existing studies do not usually focus on the effect of the type of treatment on the resistance seen. It is believed that *P. acnes* strains isolated from patients on antibiotics have more resistance than those on retinoids (tretinoin, adapalene, and isotretinoin) or BPO.\[[@ref2][@ref4][@ref8][@ref28]\] Thus, it is recommended to avoid using antibiotics for long periods and to add retinoids or BPO along with them or as the sole agents depending on the severity of acne.\[[@ref28]\] The premise that the resistance to *P. acnes* would be less in patients of BPO/oral isotretinoin has not been formally examined previously with other treatment groups. The primary objectives of our study was to: (1) Determine the prevalence of antibiotic resistance to *P. acnes* in the outpatient department attendees of a tertiary level hospital, and (2) to compare the resistance to *P. acnes* among commonly used treatment groups in India. It was our premise that patient on retinoids and/or BPO would have less resistance than patients on antibiotics (oral and/topical).

Subjects and Methods {#sec1-2}
====================

A cross-sectional study was conducted in the Department of Dermatology and Sexually Transmitted Diseases of a tertiary referral hospital and the Institute of Genomics and Integrative Biology, Delhi from November 2012 to February 2014. Ethics Committee clearance was taken at the Institute, Delhi University, and Council of Scientific and Industrial Research (CSIR) independently as it was an inter-institutional program. A total of 80 random patients of acne vulgaris were selected with the exclusion criteria of pregnant/lactating females, patients with hormonal acne, patients without comedones, and patients unwilling for sampling from their lesions. A predesigned performa was used, and patients were divided into four subgroups on the basis of the treatment they were on. Group A were treatment naïve cases with no history of previous oral or topical treatment for acne, Group B included patients who received antibiotic treatment (topical and/or oral), Group C had patients who received retinoids and/or BPO while Group D were constituted by patients who received a combination of retinoid (topical/oral) or benzyl peroxide with antibiotics. Patients, who had taken treatment for at least 4 weeks, were considered as being on treatment in the study. The acne severity was graded using the global acne grading system.\[[@ref29]\]

The identification and confirmation of genotypic mutation of *P. acnes* required a sequential step by step identification protocol based on the work of Ross *et al*.\[[@ref2]\] and Oprica *et al*.\[[@ref3]\]
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### Specimen collection and processing {#sec3-1}

After cleansing the sample area with a clean alcohol-imbibed cotton swab, open comedones (blackheads) were sampled, from the face, using a sterile comedone extractor. For a sampling of closed comedones (whiteheads), the lesion was ruptured using a 25 mm × 35 mm hypodermic needle followed by a collection of the contents using the comedone extractor.

The specimens were transported in sterile and anaerobic conditions using brain heart infusion (BHI) broth (HiMedia). The specimens were cultured on anaerobic BHI plate containing 5% defibrinated sheep blood and incubated in anaerobic condition using anaerobic jar (GasPak Anaerobic System, HiMedia) at 37°C for 7--10 days followed by sub-culturing to isolate the pure culture. Morphologically, colonies were differentiated from the basis of their color, shape, and size.\[[@ref30]\] The isolated culture was divided into two parts; one part was frozen at −80°C and another part was used to perform antimicrobial resistance study at the same time.

### Microbial identification {#sec3-2}

The initial microbial identification was performed by Gram-staining and biochemical tests, including catalase and indole tests.\[[@ref30]\] Molecular methods were used to further confirm these isolated microbes. Sequencing of 16S rRNA gene was performed to confirm the isolated organism from the acne lesions to be *P. acnes*. Genomic DNA was extracted from the pure bacterial cultures using QIAGEN QIAamp^®^ genomic DNA extraction kit and followed by 0.8% agarose (Sigma-Aldrich) gel electrophoresis to check their quality while the NanoDrop (NanoDrop spectrophotometer ND-1000) was used to estimate the concentration of genomic DNA. This step was followed by polymerase chain reaction (PCR) using two different sets of universal primers, forward primer (5'-AGAGTTTGATCCTGGCTCAG-3'), and reverse primer (5'-ACGGCTACCTTGTTACGACTT-3').\[[@ref31][@ref32][@ref33]\] QIAGEN QIAquick Gel extraction kit was used to purify the PCR product of agarose gel and followed by 16S rRNA gene sequencing using ABI-PRISM 377 automated DNA sequencer.

### Determination of minimum inhibitory concentration {#sec3-3}

Quantitative evaluation of antibacterial activity was performed by estimating the MIC for commercially available drugs on the skin isolated microbial flora from acne patients, employing the micro-well serial dilution method. Antibiotic susceptibility and resistance breakpoints were defined as prescribed by the Clinical and Laboratory Standards Institute\[[@ref23]\] as follows: Clindamycin (CL) ≥8 μg/ml, erythromycin (ERY) ≥2 μg/ml, tetracycline (TET) ≥16 μg/ml, minocycline (MINO) ≥16 μg/ml, doxycycline (DOX) ≥4 μg/ml, levofloxacin (LEVO) ≥8 μg/ml and azithromycin (AZI) ≥4 μg/ml. For the quality control of antibiotic tests the following strains were used: *P. acne* -- microbial type culture collection (MTCC) 1951, *S. aureus* -- MTCC 740, *B. cereus* -- MTCC 430, *B. subtilis* -- MTCC 121, *E. coli* -- MTCC 1586 (the MTCC and gene bank, is a national facility funded jointly by the Department of Biotechnology and the CSIR, Government of India and is at the Institute of Microbial Technology, Chandigarh).

### Statistical analysis {#sec3-4}

The data generated were compared by the Chi-square test. If the expected value in any of the cells of a contingency table was below 5, Fisher\'s exact test was used. SAS software package for windows version 9.2 was used for statistical analysis and *P* \< 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Of the 80 patients studied, there were 42 (52.5%) males and 38 (47.5%) females. The majority of the patients (83.8%) were in the age group of \<25 years with more males than females (47.5%). Using the global acne grading system,\[[@ref29]\] the majority of the patients had moderate acne (48.8%), 30% patients had mild acne, and 21.2% had severe acne.

The patients were analyzed by dividing them into four groups according to the treatment they were on for ≥4 weeks \[[Table 1](#T1){ref-type="table"}\]. There were 22 patients each in the groups not on treatment and on antibiotics alone and 18 each in the group of retinoids and/or BPO.\[[@ref34]\] There was no statistical difference among the groups with respect to age, sex, duration of disease, or severity (*P* ≥ 0.05).

###### 

An overview of the treatment groups and the therapy administered

![](IJD-61-45-g001)

A total of 52 strains of *P. acnes* were isolated (isolation rate of 65%) \[[Table 2](#T2){ref-type="table"}\] including some novel *P. acnes* strains KC874899.1, KF268368.1, KF268366.1 (<http://www.ncbi.nlm.nih.gov/nuccore/>). Of the rest, staphylococcal epidermis was the commonest organism isolated (*n* = 47).

###### 

Organisms isolated after culture of samples and genomic validation
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### Propionibacterium acnes antimicrobial susceptibility {#sec3-5}

High resistance \[[Table 3](#T3){ref-type="table"}\] was observed to macrolides-lincosamides (ERY, CL, and AZI: 98%, 90.4%, and 100%, respectively) while a low level was noted with MINO and LEVO \[[Table 3](#T3){ref-type="table"}\]. Cross resistance to CL in ERY resistant *P. acnes* was found in 46 patients (88.4%) while cross resistance between TET and DOX was seen in eight patients (15.4%). All *P. acnes* strains were resistant to at least one antibiotic (100%), none (0%) were sensitive to all the antibiotics, and 1 *P. acnes* strain was resistant to all the antibiotics (1.9%). Resistance to the macrolides was statistically more \[[Figure 1](#F1){ref-type="fig"}\] as compared to cyclines (TET, DOX, and MINO) and LEVO (*P* \< 0.001). Similarly, the resistance to DOX was more than MINO and LEVO (*P* \< 0.001) \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Susceptibility of *Propionibacterium acnes* to various antibiotics
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![*Propionibacterium acnes* resistance of commonly to used antibiotics in acne. Statistically significant difference was observed between, CL/TETs, LEVO DOX, and MINO/LEVO. ERY: Erythromycin, CL: Clindamycin, AZI: Azithromycin, TET: Tetracycline, DOX: Doxycycline, MINO: Minocycline, LEVO: levofloxacin. NS: not significant](IJD-61-45-g004){#F1}

### Minimum inhibitory concentration values {#sec3-6}

The MIC values of the strains are listed in [Table 4](#T4){ref-type="table"}. The macrolides, CL, and TET had the highest MIC90 values, followed by DOX, MINO, and LEVO.

###### 

MICs of antimicrobials against *Propionibacterium acnes*
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### Propionibacterium acnes antimicrobial resistance in the treatment groups {#sec3-7}

The treatment naïve group \[[Table 5](#T5){ref-type="table"}\] had high resistance to macrolides and CL (75--100%), followed by TET and DOX (33--41%), with a low resistance to MINO and LEVO (0--8.3%). A similar trend was noticed in the other treatment groups.

###### 

Resistance patterns to antibiotics in the treatment groups\*
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As the 4^th^ group \[[Table 1](#T1){ref-type="table"}\] on combination therapy had heterogeneous treatment interventions this was not included in the intergroup analysis. On intergroup comparison, there was no statistical difference among the groups (*P* \> 0.05). While the lowest number of resistant strains was seen in the group on retinoids and/or BPO, the difference with the other groups was not statistically significant (*P* \> 0.05).

Comparison of the prevalence of antibiotic resistance to *P. acnes* in the subgroups according to age, sex, disease duration, and severity of acne did not reveal any significant difference except in CL resistance which was seen in patients having duration of disease of more than 2 years (*P* = 0.049).

Discussion {#sec1-4}
==========

Our study revealed a high level of resistance to macrolides and CL (98% to ERY, 90.4% to CL, and 100 % to AZI) with a low resistance to MINO (1.9%) and LEVO (9.6%). The MIC values also largely correlated with the high resistant antibiotics with a high MIC90 seen to macrolides and CL (≥256 μg/ml), and low MIC90 values to MINO (8 μg/ml) and LEVO (4 μg/ml). On comparison of the treatment groups, the least number of resistant strains were seen in the retinoids and/or BPO group, but there was no statistically significant difference within the treatment groups with respect to the antibiotic resistant strains.

Though there are numerous studies on antibiotic resistance in acne,\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref21]\] there is no study that has compared various treatment groups, namely antibiotics and retinoids and/or BPO, with respect to the pattern of antibiotic resistance.

There are three issues that are relevant to a study of resistance in acne vulgaris. The first is the presence of resistant *P. acnes* to various antibiotics, which has been noticed with most macrolides and TETs and is due to the long treatment duration and concomitant use of oral and topical antibiotics.\[[@ref1][@ref2][@ref3]\] The worldwide data on resistance \[[Table 6](#T6){ref-type="table"}\] should be interpreted with respect to regional prescription practices.\[[@ref2][@ref3]\] The low levels of resistance in Hungary\[[@ref2]\] is due to the restricted acne prescriptions. The use of multiple adjunctive therapies accounts for the high levels of resistance in Spain \[[Table 6](#T6){ref-type="table"}\].\[[@ref2]\] Oprica *et al*.\[[@ref3]\] reported a variable resistance, ranging from 83% in Croatia, 60% in Italy to 0% in The Netherlands. There was more resistance in the Southern Europe as compared to the Western Europe. Notably in countries with no "nonhospital" use of antibiotics (Netherlands) there was no problem of resistance. Though it is has been proposed that resistance across certain areas may be explained by specific mutations and clones of *P. acnes*\[[@ref36]\] this has not been consistently proved.\[[@ref37]\]

###### 

An overview of seminal studies on antibiotic resistance in acne vulgaris
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Our study largely mirrors the trend of high resistance to macrolides and CL and low level of resistance to MINO and LEVO has seen across the world \[[Table 6](#T6){ref-type="table"}\]. This is due to prescription practices that cause macrolides resistance which drives resistance to CL and often to TET. The high levels in our study are due to the widespread use of macrolides and CL, with a prolonged course of therapy, mostly due to the nonadherence by patients of the physicians advice to restrict antibiotic usage and duration. Furthermore, "over the counter" availability of drugs without prescription is a major contributing factor leading to misuse of the antibiotics. The universal (100%) resistance to AZI is akin to another study from Mexico\[[@ref11]\] and highlights the misuse of this drug for acne. Its use in acne is surprising as it is essentially a macrolides, a class to which resistance has been known to occur.\[[@ref1][@ref2][@ref3]\] As AZI is commonly used to treat a variety of systemic infections, its use should be restricted and discouraged in acne.\[[@ref27][@ref35]\] The resistance to TET and DOX was high in our study with low resistance to MINO \[[Figure 1](#F1){ref-type="fig"}\]. The low resistance to MINO is in consonance with studies across the world\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18]\] and is probably as the drug is highly lipophilic and thus has a better penetration leading to enhanced efficacy. LEVO is a reserve drug for acne\[[@ref10][@ref11][@ref38][@ref39]\] that is prescribed in Japan. Though low resistance levels have been seen in our study, the drug should be used sparingly, lest it is misused, such as AZI.

The second important issue that is not well-researched is whether various therapeutic interventions can impact on the level of resistance.\[[@ref28]\] This is largely dependent on the level of background resistance, a high level of which was seen in the treatment naïve group \[[Table 5](#T5){ref-type="table"}\]. Coates *et al*.\[[@ref1]\] had observed that it is difficult to correlate the use of antibiotics with the emergence of resistant commensal organisms. A study from Australia\[[@ref15]\] found that patients who had not received any antibiotics for last 4 months had no resistance. We cannot rule out the use of antibiotics for nondermatological indications in the treatment naïve group, which is a possible reason for the high levels of resistance. Interestingly, another study\[[@ref18]\] revealed that patients may have resistance to antibiotics which they have never been used before. This has been explained by the dissemination of resistance by person-to-person contact, which explained the prevalence of resistant *P. acnes* in household contacts of patients with acne.\[[@ref2]\] Thus, the high resistance levels in the treatment naïve group can be explained by, the colonization with resistant clones, dissemination of antibiotic resistant genes and the possible treatment with antibiotics for other diseases.

It is believed that the antibiotic group, due to selection pressure, would have more resistance than the treatment naïve group, but this was not seen in our study \[[Table 5](#T5){ref-type="table"}\]. While studies have shown that resistance levels correlate with antibiotic usage,\[[@ref2][@ref3]\] other authors\[[@ref7]\] have not found this correlation, similar to our work. Two studies\[[@ref10][@ref12]\] have found that prior antibiotic therapy tended to result in higher mean MICs of isolates, although the differences were not statistically significant. A study from Korea\[[@ref10]\] found that while the MIC tended to be higher in the patient group with prior use of antimicrobial agents, this was statistically significant only for DOX. As resistant strains are mutation based and permanent, they will persist\[[@ref37][@ref41]\] and this explains the lack of correlation among the group on antibiotics vis-a-vis the treatment naïve group \[[Table 5](#T5){ref-type="table"}\].

The lack of significant difference between the retinoids and/or BPO group and the antibiotic group is an interesting finding as it is conventionally believed that being "nonantibiotics," resistant strains are not seen with their use. The effect of BPO against sensitive and resistant strains of *P. acnes*\[[@ref35]\] is time dependent.\[[@ref41]\] A study\[[@ref41]\] revealed that at the end of 4 weeks though the ERY/CL resistant strains decreased, they were not completely eliminated.\[[@ref40]\] Ross *et al*. found that in Spain,\[[@ref2]\] BPO did not reduce resistant strains, due to the high background resistance to macrolides/CL, similar to our study. Oprica *et al*.\[[@ref41]\] elegantly demonstrated that patients on isotretinoin had resistant strains even post-therapy in spite of a favorable clinical response. Coates *et al*.\[[@ref42]\] had also demonstrated that isotretinoin did not significantly reverse the resistant strains of *P. acnes*. Our study reiterates the finding that retinoids and/or BPO cannot always eliminate or markedly reduce the resistant strains in acne\[[@ref41][@ref42]\] especially if there is a high background resistance as seen in our study \[[Table 5](#T5){ref-type="table"}\]. However, it is possible that if a longer period of treatment was administered, this group of patients might have had a markedly reduced *P. acnes* resistance; though we may point out that in our work a high background resistance was noted and this resistance is mutational based and is not reversible.\[[@ref2][@ref3]\]

The method of isolation of *P. acnes* is an important aspect\[[@ref22]\] as different sampling/study methodologies will likely target anatomically distinct *P. acnes* populations with, at least theoretically, distinct pathogenic potentials. *P. acnes* at the stratum corneum is, like *S. epidermidis*, a commensal. Recent studies on genomic analysis of *P. acnes* have led to the discovery of various phylotypes (IA 1, IA 2, IB, IC, II, and III).\[[@ref43]\] Techniques such as swab and scrape are inappropriate to isolate *P. acnes*.\[[@ref22]\] Sadly, there is a lack of uniformity in studies with a large number of studies using surface skin isolation methods,\[[@ref1][@ref2][@ref3][@ref4][@ref15]\] which may not always reflect the pathogenic strains of *P. acnes*.\[[@ref22]\] The confirmation of the organism requires the use 16S rRNA based PCR and sequencing or other techniques such as fluorescence *in situ* hybridization, which has been used in a few studies.\[[@ref8][@ref9][@ref10][@ref16][@ref18]\] Our technique included a combination of follicular content sampling and genomic confirmation, which makes our isolation and identification of *P. acnes* accurate though it does add to the cost of the study \[[Table 6](#T6){ref-type="table"}\].

The inherent drawback in our study is that we did not study discrete groups of patients, on a single drug, which though is an ideal scenario, is not always practiced. Our groups represented a realistic prescription practice that has been observed by Coates *et al*.,\[[@ref1]\] wherein topical and oral agents are used in succession and in combination. Another drawback, largely due to the cost constraints of our protocol, was the lack of sequential (weekly) isolation and confirmation of resistant *P. acnes*, which could have helped to map the sequential decrease in resistant strains on BPO. The lack of any statistically significant changes may also be partially contributed by the low sample size and power of the present study.

Antibiotic resistance in *P. acnes* presents a worldwide problem for the treatment of acne and geographical variations in resistance are bound to be present \[[Table 6](#T6){ref-type="table"}\]. Thus, each country has to enforce a specific antibiotic policy for acne. Though it is difficult to defend the often long-term use of antibiotics for acne, until effective new nonantibiotic treatments for acne with acceptable side effects are available, antibiotics will probably remain the preferred drug in moderate grades of acne.\[[@ref28][@ref44][@ref45]\] To minimize the resistance problem certain measures are advocated, like avoiding antibiotics for milder forms of acne and using antibiotics in combination with topical retinoids or BPO if antibiotics must be administrated for longer than 2 months.\[[@ref27][@ref28][@ref45][@ref46][@ref47]\] Probably adding other agents such as zinc and azealic acid may help to obviate the development of resistance.\[[@ref27][@ref47]\] However, the misuse of antibiotics in acne, if they exceed the MIC levels "*in vitro*," will lead to an epidemiological problem and predispose to transfer of resistance to other organisms and patients. Most importantly higher MIC may drive the antibiotics out of the realms of clinical use as breakpoint levels will be reached soon with most antibiotics.
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**What is new?**

The type of therapy may not affect the resistance levels to macrolideslincosamides if there is a high background resistanceMinocycline resistance is still low and this drug may be a valid treatment optionBPO/isotretinoin are effective drugs though they may not markedly affect the resistant strains, though a prolonged duration of therapy may help.
